BLA 761070 · Astrazeneca Ab
Fasenra
Benralizumab · Injection · Interleukin-5 Receptor alpha-directed Cytolytic Antibody
NovelOrphanLast checked: Nov 20, 2026Latest source record: May 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 14, 2017
Approved uses
5
Original approval plus efficacy supplements
Registered trials
73
37 Phase 3, 11 recruiting
FAERS reports
20,994
13,564 serious, 2,114 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 13, 2026.
FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. ( 1.1 ) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.2 ) • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. ( 1.3 ) Limitations of Use : Not for relief of acute bronchospasm or status asthmaticus. (1.1) 1.1 Asthma FASENRA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. Limitations of Use: • FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Eosinophilic Granulomatosis with Polyangiitis FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1.3 Hypereosinophilic Syndrome FASENRA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause.
Mechanism: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils. In an in vitro setting, the absence of fucose in the Fc domain of benralizumab facilitates binding (45.5 nM) to FcɣRIII receptors on immune effector cells, such as natural killer (NK) cells, leading to apoptosis of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC). Inflammation is an...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 2026 Supplement 23 · Efficacy OrphanLetterLabel
- Sep 17, 2024 Supplement 21 · Efficacy OrphanLabelLetter
- Apr 5, 2024 Supplement 20 · Efficacy LabelLetter
- Oct 3, 2019 Supplement 5 · Efficacy LabelLetter
- Nov 14, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- FASENRA · BENRALIZUMAB 30MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Benralizumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01928771 · 2,681 participants · Start Sep 19, 2013 · Primary completion Apr 5, 2016
Drug: Benralizumab; Placebo · For: Asthma
Sites: Foley, Alabama; Huntsville, Alabama; Mobile, Alabama · 275 sites in all
- Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 AgonistPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01914757 · 2,508 participants · Start Aug 2013 · Primary completion Mar 2016
Drug: Benralizumab; Placebo · For: Asthma
Sites: Andalusia, Alabama; Birmingham, Alabama; Flagstaff, Arizona · 214 sites in all
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02155660 · 2,255 participants · Start Jun 25, 2014 · Primary completion Apr 9, 2018
Drug: Benralizumab Arm A; Benralizumab Arm B and 2 more · For: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Montgomery, Alabama · 356 sites in all
- A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABAPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02258542 · 2,133 participants · Start Nov 19, 2014 · Primary completion Oct 18, 2017
Drug: Benralizumab; Benralizumab · For: Asthma
Sites: Andalusia, Alabama; Birmingham, Alabama; Scottsboro, Alabama · 429 sites in all
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04718389 · 1,717 participants · Start Jan 26, 2021 · Primary completion Sep 14, 2025
Drug: GSK3511294 (Depemokimab); Mepolizumab and 3 more · For: Asthma
Sites: Birmingham, Alabama; Scottsboro, Alabama; Litchfield Park, Arizona · 397 sites in all
- Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02138916 · 1,656 participants · Start Jun 13, 2014 · Primary completion Apr 10, 2018
Drug: Benralizumab Arm A; Benralizumab Arm B and 1 more · For: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Sites: Andalusia, Alabama; Birmingham, Alabama; Dothan, Alabama · 407 sites in all
- Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled AsthmaPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01238861 · 964 participants · Start Dec 2010 · Primary completion Mar 2013
Drug: Benralizumab 2 mg; Benralizumab 20 mg and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 74 sites in all
University Hospital, LilleAcademic, hospital or other
NCT06501807 · 900 participants (planned) · Start Jul 11, 2024 · Primary completion Sep 2, 2034
Drug: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval). · For: Rhinosinusitis Chronic; Nasal Polyps
Sites: Lille, France · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma3,144
- dyspnoea2,109
- death1,738
- drug ineffective1,580
- pneumonia1,218
- cough1,111
- product dose omission issue1,078
- headache973
- wheezing791
- fatigue679
- malaise638
- inappropriate schedule of product administration619
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 910 |
| 2019 | 1,649 |
| 2020 | 1,709 |
| 2021 | 2,104 |
| 2022 | 1,827 |
| 2023 | 2,296 |
| 2024 | 3,669 |
| 2025 | 3,546 |
| 2026 | 3,269 |
Recalls
1 FDA enforcement reports for this application.
Oct 8, 2025 · Class II · Ongoing
Lack of Assurance of Sterility:
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fasenra (Benralizumab)
2024 spending
$75.9M
Beneficiaries
3,087
13,139 claims
Per beneficiary
$24,574
$5,748.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $43,358,082 |
| 2021 | $54,241,546 |
| 2022 | $65,644,342 |
| 2023 | $69,166,950 |
| 2024 | $75,859,049 |
Part B: Fasenra* (Benralizumab*) · HCPCS J0517
2024 spending
$241M
Beneficiaries
9,899
50,136 claims
Per beneficiary
$24,374
2024 ASP limit $167.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $180,879,417 |
| 2021 | $197,482,084 |
| 2022 | $216,900,354 |
| 2023 | $231,829,729 |
| 2024 | $241,276,554 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Pitre T, Lupas D, Mah J, et al. · COPD 2025 · Systematic Review, Network Meta-Analysis
- Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).
Chupp G, Nagase H, Skowasch D, et al. · Am J Respir Crit Care Med 2026 · Multicenter Study, Randomized Controlled Trial
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence.
Cai S, Xu S, Zhao Y, et al. · Allergy 2025 · Meta-Analysis, Systematic Review
- Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis.
Chu AWL, Oykhman P, Chu X, et al. · J Allergy Clin Immunol 2025 · Comparative Study, Network Meta-Analysis
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.